Data Factory
Reading the graph
Reading the graph
Venture Capital
Orinda, CA
Greenoaks is a concentrated, long-term partner to extraordinary founders building generational businesses.
Data as of (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built and rebuilt at most every 15 minutes.
| Fund | Vintage | Lifecycle | Form D sold | GAV | LPs |
|---|---|---|---|---|---|
| GCP 099 | 2024 | Early deployment | n/a | $60.3M | 0 |
| GCP 104 | 2024 | Early deployment | n/a | $88.0M | 0 |
| GCP 061 | 2024 | Early deployment | n/a | $237M | 0 |
| GCP 083 | 2023 | Active deployment | n/a | $88.7M | 0 |
| GCP 098 | 2023 | Active deployment | n/a | $2.0B | 0 |
| GCP 090 | 2023 | Active deployment | n/a | $113M | 0 |
| GCP 094 | 2023 | Active deployment | n/a | $42.5M | 0 |
| Greenoaks Capital Opportunities Fund V LP | 2023 | Active deployment | n/a | n/a | 1 |
| GCP 088 | 2022 | Active deployment | n/a | $16.1M | 0 |
| GCP 085 | 2022 | Active deployment | n/a | $1.9B | 0 |
| GCP 092 | 2022 | Active deployment | n/a | $31.3M | 0 |
| GCP 079 | 2022 | Active deployment | n/a | $78.1M | 0 |
| GCP 076 | 2022 | Active deployment | n/a | $179M | 0 |
| GCP 086 | 2022 | Active deployment | n/a | $65.0M | 0 |
| GCP 077 | 2022 | Active deployment | n/a | $23.8M | 0 |
| GCP 070 | 2022 | Wound down | n/a | $1.6M | 0 |
| GCP 080 | 2022 | Active deployment | n/a | $10.5M | 0 |
| GCP 087 | 2022 | Active deployment | n/a | $12.5M | 0 |
| GCP 096 | 2022 | Active deployment | n/a | $30.4M | 0 |
| GCP 095 | 2022 | Active deployment | n/a | $23.2M | 0 |
| GCP 081 | 2022 | Active deployment | n/a | $106M | 0 |
| GCP 082 | 2022 | Active deployment | n/a | $34.9M | 0 |
| GCP 091 | 2022 | Active deployment | n/a | $106M | 0 |
| GCP 084 | 2022 | Active deployment | n/a | $423M | 0 |
| GCP 078 | 2022 | Active deployment | n/a | $42.6M | 0 |
| Company | State | Stage | Round size | Partner | Attribution | Observed |
|---|---|---|---|---|---|---|
| Medici Brands | n/a | Series b | $250M | Neil Shah | Confirmed | Sep 2, 2026 |
| Mytra | n/a | Series c | $120M | n/a | Unknown | Jan 15, 2026 |
| Investor | Co-investor | Shared deals | Shared companies | Last observed | Strength |
|---|---|---|---|---|---|
| Liquid 2 Ventures, LLC | Greenoaks Capital | 1 | 1 | Jan 15, 2026 | One time |
| Valor Equity Partners | Greenoaks Capital | 1 | 1 | Sep 2, 2026 | One time |
| Abstract Ventures | Greenoaks Capital | 1 | 1 | Jan 15, 2026 | One time |
| Greenoaks Capital | Peter Rahal | 1 | 1 | Sep 2, 2026 | One time |
| Greenoaks Capital | Avenir Growth | 1 | 1 | Jan 15, 2026 | One time |
| Greenoaks Capital | Kivu Ventures | 1 | 1 | Jan 15, 2026 | One time |
| RyderVentures | Greenoaks Capital | 1 | 1 | Jan 15, 2026 | One time |
| Iconiq Capital, LLC | Greenoaks Capital | 1 | 1 | Sep 2, 2026 | One time |
| Greenoaks Capital | Lineage Capital, LLC | 1 | 1 | Jan 15, 2026 | One time |
Also named here, with no published line of their own (reach them through the firm): Neil Shah (Partner).
Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan